Please login to the form below

Not currently logged in

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

Obagi treatments

Merz Pharma has elected not to raise its $385m offer for dermatology specialist Obagi Medical Products, clearing the way for a takeover by rival Valeant Pharmaceuticals.

Merz made an offer for Obagi last week that trumped an earlier $360m offer from Valeant but bowed out of the bidding after Valeant came back to the table with a $24-per-share offer that valued the business at around $418m.

"Obagi was an opportunity worth pursuing given its complementary fit," said Merz chief executive Philip Burchard in a statement.

"However, Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements," he added, noting that Merz will be exploring other acquisition opportunities.

Obagi's management seemed to favour a merger with Valeant, and the withdrawal of Merz now sets the clock ticking on Valeant's bid which expires on April 23 and is conditional on a majority of Obagi shares being tendered by the midnight deadline.

Analysts have suggested that it is unlikely any other buyers will emerge at this late stage.

The offer for Obagi comes after a string of acquisitions by Valeant in the dermatology sector. Last year, it bought skincare specialist Medicis in a $2.6bn deal that added Botox rival Dysport (abobotulinumtoxin A) to its portfolio along with a range of wrinkle treatments. This was after earlier deals for Johnson & Johnson's Ortho Dermatologics and Sanofi's Dermik skincare business.

Obagi would add products such as the Nu-Derm range of moisturisers and prescription products distributed through dermatology and plastic surgery clinics for conditions such as premature aging, photodamage, hyperpigmentation, acne, sun damage and facial redness.

9th April 2013

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...